Oxybutynin transdermal - Allergan

Drug Profile

Oxybutynin transdermal - Allergan

Alternative Names: CS 801; Gelnique Gel 10%; Kentera; MM 801; Oxybutynin patch - Allergan; Oxybutynin topical gel - Allergan; Oxytrol

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Watson Laboratories
  • Developer Allergan; Daiichi Sankyo Company; Meiji Dairies Corporation
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 12 Feb 2015 Launched for Overactive bladder in Switzerland, Norway and New Zealand (Transdermal) prior to February 2015
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 25 Jan 2013 The US FDA has approved the oxybutynin patch for treatment of Overactive bladder (OAB) in women as an over-the-counter (OTC) medication, as Oxytrol for Women. The product will remain available by prescription only in men with OAB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top